Two Sigma Advisers
TRML

Two Sigma Advisers’s Tourmaline Bio TRML Stock Holding History

Two Sigma Advisers’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,219
Closed -$186K – 2550
2025
Q1 		$186K Buy
+12,219
New +$196K ﹤0.01% 2155
2024
Q4 		– Sell
-10,119
Closed -$260K – 2538
2024
Q3 		$260K Sell
10,119
-52,300
-84% -$873K ﹤0.01% 1970
2024
Q2 		$803K Buy
62,419
+42,300
+210% +$681K ﹤0.01% 1666
2024
Q1 		$461K Sell
20,119
-15,000
-43% -$529K ﹤0.01% 1906
2023
Q4 		$919K Buy
35,119
+12,456
+55% +$249K ﹤0.01% 1678
2023
Q3 		$637K Buy
22,663
+13,913
+159% +$407K ﹤0.01% 1704
2023
Q2 		$266K Buy
8,750
+6,200
+243% +$158K ﹤0.01% 2018
2023
Q1 		$47.9K Sell
2,550
-820
-24% -$13.5K ﹤0.01% 2451
2022
Q4 		$34.4K Buy
+3,370
New +$54.2K ﹤0.01% 2391
2021
Q4 		– Sell
-1,140
Closed -$155K – 2809
2021
Q3 		$155K Sell
1,140
-1,170
-51% -$160K ﹤0.01% 2289
2021
Q2 		$339K Buy
+2,310
New +$354K ﹤0.01% 2100

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Two Sigma Advisers's TRML Position: Q2 2025 in Review

Two Sigma Advisers sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 12,219 shares — an estimated $186K sold.

Two Sigma Advisers first reported a position in TRML in Q2 2021 and held it in 11 quarters. The position peaked at $919K in Q4 2023. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Two Sigma Advisers reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 12,219 Tourmaline Bio shares in Q2 2025, an estimated $186K.
  • Two Sigma Advisers first reported a position in Tourmaline Bio in Q2 2021 and held it in 11 quarters.
  • Two Sigma Advisers's Tourmaline Bio position peaked at $919K in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.